New Kids on the Block: RNA-Based Influenza Virus Vaccines

Overview

Journal Vaccines (Basel)

Date 2018 Apr 5

PMID 29614788

Citations 46

Authors

Francesco Berlanda Scorza

Norbert Pardi

Affiliations

Soon will be listed here.

Abstract

RNA-based immunization strategies have emerged as promising alternatives to conventional vaccine approaches. A substantial body of published work demonstrates that RNA vaccines can elicit potent, protective immune responses against various pathogens. Consonant with its huge impact on public health, influenza virus is one of the best studied targets of RNA vaccine research. Currently licensed influenza vaccines show variable levels of protection against seasonal influenza virus strains but are inadequate against drifted and pandemic viruses. In recent years, several types of RNA vaccines demonstrated efficacy against influenza virus infections in preclinical models. Additionally, comparative studies demonstrated the superiority of some RNA vaccines over the currently used inactivated influenza virus vaccines in animal models. Based on these promising preclinical results, clinical trials have been initiated and should provide valuable information about the translatability of the impressive preclinical data to humans. This review briefly describes RNA-based vaccination strategies, summarizes published preclinical and clinical data, highlights the roadblocks that need to be overcome for clinical applications, discusses the landscape of industrial development, and shares the authors' personal perspectives about the future of RNA-based influenza virus vaccines.

Citing Articles

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.

Cheng Z, Ma J, Zhao C Vaccines (Basel). 2025; 12(12.

PMID: 39772044 PMC: 11680418. DOI: 10.3390/vaccines12121382.

The need for novel influenza vaccines in low- and middle-income countries: A narrative review.

Spinardi J, Thakkar K, Welch V, Jagun O, Kyaw M Braz J Infect Dis. 2024; 29(1):104465.

PMID: 39642677 PMC: 11664161. DOI: 10.1016/j.bjid.2024.104465.

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines.

Hauguel T, Sharma A, Mastrocola E, Lowry S, Maddur M, Hu C NPJ Vaccines. 2024; 9(1):183.

PMID: 39375384 PMC: 11488230. DOI: 10.1038/s41541-024-00980-3.

mRNA vaccines for infectious diseases - advances, challenges and opportunities.

Pardi N, Krammer F Nat Rev Drug Discov. 2024; 23(11):838-861.

PMID: 39367276 DOI: 10.1038/s41573-024-01042-y.

Vaccines for Respiratory Viruses-COVID and Beyond.

Rajanala K, Upadhyay A Vaccines (Basel). 2024; 12(8).

PMID: 39204059 PMC: 11360283. DOI: 10.3390/vaccines12080936.

References

Paules C, Marston H, Eisinger R, Baltimore D, Fauci A . The Pathway to a Universal Influenza Vaccine. Immunity. 2017; 47(4):599-603. DOI: 10.1016/j.immuni.2017.09.007. View

Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C . Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006; 108(13):4009-17. DOI: 10.1182/blood-2006-04-015024. View

Schnee M, Vogel A, Voss D, Petsch B, Baumhof P, Kramps T . An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl Trop Dis. 2016; 10(6):e0004746. PMC: 4918980. DOI: 10.1371/journal.pntd.0004746. View

Memoli M, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K . Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis. 2014; 60(5):693-702. PMC: 4342672. DOI: 10.1093/cid/ciu924. View

Lindgren G, Ols S, Liang F, Thompson E, Lin A, Hellgren F . Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Front Immunol. 2017; 8:1539. PMC: 5693886. DOI: 10.3389/fimmu.2017.01539. View

Ross J, SULLIVAN T . Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood. 1985; 66(5):1149-54. View

Monto A, Petrie J, Cross R, Johnson E, Liu M, Zhong W . Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis. 2015; 212(8):1191-9. DOI: 10.1093/infdis/jiv195. View

Bahl K, Senn J, Yuzhakov O, Bulychev A, Brito L, Hassett K . Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017; 25(6):1316-1327. PMC: 5475249. DOI: 10.1016/j.ymthe.2017.03.035. View

Lin A, Liang F, Thompson E, Vono M, Ols S, Lindgren G . Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination. J Immunol. 2017; 200(1):286-294. DOI: 10.4049/jimmunol.1701005. View

10.

Perri S, Greer C, Thudium K, Doe B, Legg H, Liu H . An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003; 77(19):10394-403. PMC: 228391. DOI: 10.1128/jvi.77.19.10394-10403.2003. View

11.

Chahal J, Khan O, Cooper C, McPartlan J, Tsosie J, Tilley L . Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A. 2016; 113(29):E4133-42. PMC: 4961123. DOI: 10.1073/pnas.1600299113. View

12.

Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet J . Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993; 23(7):1719-22. DOI: 10.1002/eji.1830230749. View

13.

Andrews S, Graham B, Mascola J, McDermott A . Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb Perspect Biol. 2017; 10(7). PMC: 6028068. DOI: 10.1101/cshperspect.a029413. View

14.

Martin S, Paoletti E, Moss B . Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem. 1975; 250(24):9322-9. View

15.

Richner J, Himansu S, Dowd K, Butler S, Salazar V, Fox J . Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017; 168(6):1114-1125.e10. PMC: 5388441. DOI: 10.1016/j.cell.2017.02.017. View

16.

Lutz J, Lazzaro S, Habbeddine M, Schmidt K, Baumhof P, Mui B . Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines. 2017; 2:29. PMC: 5648897. DOI: 10.1038/s41541-017-0032-6. View

17.

Kranz L, Diken M, Haas H, Kreiter S, Loquai C, Reuter K . Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534(7607):396-401. DOI: 10.1038/nature18300. View

18.

Wu N, Zost S, Thompson A, Oyen D, Nycholat C, McBride R . A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017; 13(10):e1006682. PMC: 5667890. DOI: 10.1371/journal.ppat.1006682. View

19.

Brito L, Kommareddy S, Maione D, Uematsu Y, Giovani C, Scorza F . Self-amplifying mRNA vaccines. Adv Genet. 2015; 89:179-233. DOI: 10.1016/bs.adgen.2014.10.005. View

20.

Halasa N, Gerber M, Chen Q, Wright P, Edwards K . Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis. 2008; 197(10):1448-54. PMC: 3773726. DOI: 10.1086/587643. View